128 related articles for article (PubMed ID: 77399)
1. Adjuvant hormono-chemotherapy in operable breast cancer.
Wilson R; Hanham IW; Mair G; Drake SR; Derry CD; McKenzie C; Stoll BA; Boesen E; Skeggs DB; Senanayake F
Lancet; 1978 May; 1(8073):1101. PubMed ID: 77399
[No Abstract] [Full Text] [Related]
2. Surgical adjuvant trials in the United States.
Rozencweig M; Von Hoff DD; Allegra JC; Muggia FM
Eur J Cancer (1965); 1980; Suppl 1():173-7. PubMed ID: 7032929
[No Abstract] [Full Text] [Related]
3. Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer.
Cavalli F; Alberto P; Jungi F; Brunner K; Martz G
Eur J Cancer (1965); 1980; Suppl 1():125-9. PubMed ID: 7032922
[No Abstract] [Full Text] [Related]
4. Systemic adjuvant therapy and breast cancer.
Rubens RD
Radiother Oncol; 1985; 4(2):105-10. PubMed ID: 3934715
[No Abstract] [Full Text] [Related]
5. Present status of CMF adjuvant therapy in operable breast cancer.
Bonadonna G
Int J Radiat Oncol Biol Phys; 1977; 2(3-4):237-40. PubMed ID: 324955
[No Abstract] [Full Text] [Related]
6. Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Eur J Cancer (1965); 1980; Suppl 1():189-95. PubMed ID: 7032932
[No Abstract] [Full Text] [Related]
7. Adjuvant treatment in operable breast cancer.
Goldhirsch A
J Steroid Biochem; 1985 Dec; 23(6B):1155-60. PubMed ID: 3912622
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
9. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Mouridsen HT; Palshof T; Engelsman E; Sylvester R
Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
[No Abstract] [Full Text] [Related]
10. Preoperative chemotherapy for fungating breast cancer.
Kumar A; Shah LL; Khanna S; Khanna NN
J Surg Oncol; 1987 Dec; 36(4):295-8. PubMed ID: 3695536
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of a continuous study protocol with adjuvant chemotherapy in primary operable breast carcinoma].
Cavalli F; Jungi F; Alberto P; Martz G; Brunner KW
Haematol Blood Transfus; 1978; 22():61-6. PubMed ID: 374200
[No Abstract] [Full Text] [Related]
12. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
Mouridsen HT; Palshof T; Brahm M; Rahbek I
Cancer Treat Rep; 1977; 61(1):47-50. PubMed ID: 324620
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.
Mouridsen HT; Palshof T
Prog Clin Biol Res; 1977; 12():459-66. PubMed ID: 335404
[No Abstract] [Full Text] [Related]
14. A randomized trial of postoperative five-versus three-drug chemotherapy after mastectomy: a Cancer and Leukemia Group B (CALGB) study.
Weiss RB; Tormey DC; Holland F; Weinberg VE; Lesnick G; Perloff M; Falkson G; Glidewell OJ
Recent Results Cancer Res; 1982; 80():170-6. PubMed ID: 7036280
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK
Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926
[No Abstract] [Full Text] [Related]
16. Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial.
Heuson JC; Sylvester R; Engelsman E
Eur J Cancer (1965); 1980; Suppl 1():113-7. PubMed ID: 7032920
[No Abstract] [Full Text] [Related]
17. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Levitt SH; Potish RA
Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Rossi A; Bonadonna G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1977; (62):134-42. PubMed ID: 341246
[No Abstract] [Full Text] [Related]
19. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
[No Abstract] [Full Text] [Related]
20. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.
Ludwig Breast Cancer Study Group
Cancer Res; 1985 Sep; 45(9):4454-9. PubMed ID: 2862995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
